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Results. In type 1 VWD mutations are located throughout the VWF gene from the promoter 
region to exon 52 and the majority are missense mutations (75%), whereas splice, deletion, 
nonsense, insertion, duplication, and large in-frame deletions mutations comprise minor 
proportions. The most common locations for mutations in type 2A WVD are: the A2 domain 
(p.Arg1315Cys, p.Arg1374Cys and p.Arg1374His) , D3 domain (missense mutations are 
located in ex22 and 25 to 28, many introducing/substituting cysteine residues; replacement of 
p.Cys1130 is the most common change), D2 domain (mutations are recessively inherited and 
are located in ex11 to 16), and CK domains (mutations affect ex51 to 52). Mutations in type 
2B and 2M are located in the A1 domain (ex 28). Type 2N VWD is caused by mutations in ex 
17-20 and 24-25 (missense mutations or null allele). The most frequent mutation in the 
European populations is p.Arg854Gln, for which ∼1% of individuals are heterozygous. In type 
3 VWD the mutation location is 5′ VWF-Ex52 (missense mutations or null allele).  
Conclusions. VWF mutations are located throughout the VWF gene, resulting in a wide range 
of mutation types that cause quantitative and qualitative disorders. VWF protein is involved in 
several processes that can be damaged by mutation, and the varying phenotypes in VWD 
illustrate the processes that are impaired.  
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Introduction. Gastric cancer is a neoplasm with a starting point in the gastric mucosa, 
representing one of the most common malignant visceral locations. Although a decreasing 
incidence globally, gastric cancer remains one of the most common causes of cancer death. 
Diagnosed in the early stage, it is curable, but unfortunately, most cases are identified late, in 
advanced stages.  
Aim of the study. Elucidation of predisposing factors and molecular mechanisms underlying 
gastric cancer development.  
Materials and methods. Exploring bibliographic sources using databases: PubMed, Google 
Scholar  
Results. Gastric cancer presents a multifactorial pathology caused by the interaction between 
environmental factors - Helicobacter Pylori, major cancer agent - and the genetic factors of the 
host organism. Genetic predisposition plays a major role in gastric carcinogenesis, as there are 
classes of genes involved in mucosal protection, immune response to H. pylori infection, 
carcinogen detoxification, antioxidant protection, DNA damage repair and ability to cell 
proliferation. The protective genes of the gastric mucosa are the mucin genes. The subtypes 
MUC1 (G allele at rs4072037), MUC2, MUC5AC, MUC6 and the genes of the trefoil peptide-
pS2 peptide, factor 1 (TFF1), spasmolytic polypeptide (SP) and intestinal ITF factor). 
Detoxification genes: cytochrome P450 (CYP450) linked to metabolism I-CYP1A1 
(Ile462Val), CYP2E1 and CYP2C19. Glutathione S-transferases (GSTs) in Phase II play a role 
in protecting cells against the onslaught of chemical carcinogens. The pro and anti-
inflammatory genes IL1B, TNF, LTA, IL 6, IL1RN, IL 10 and TGF B, play a key role in the 
development of CG.DNA-repair genes include methylenetetrahydrofolate reductase (MTHFR- 
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C677T mutation, XRCC1 gene (Arg194Trp), HOGG1 with TT genotype, xeroderma 
pigmentosum (XPF) (rs744154) increase susceptibility. Tumor suppressor genes: p53 (Arg / 
Arg), p53CD72 associated with genetic susceptibility to gastric cancer is an important 
biomarker. H. pylori infection and p53 mutation have been shown to have a synergistic effect. 
NM23 is the first confirmed suppressor gene for tumor metastases.  
Conclusions. The study is based on the analysis of genetic variants that confer a higher risk of 
CG and their interactions with environmental factors, respectively H. pylori infection. 
Candidate gene polymorphisms in gastric cancer susceptibility. A deeper understanding of the 
factors involved in the development and progression of CG may allow the identification of 
persons at risk and can provide useful predictive information for the subgroups of patients who 
need early treatment or surveillance strategies.  
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Introduction. Papillary Thyroid Cancer (PTC) is taking the 1st place in malign processes of 
endocrine system, being also the most studied problem in cases of thyroid gland cancer. PTC 
is taking 40-85% from the total of the thyroid cancer in the past few decades. This is because 
of the human activity in the past- pollution of the environment, the rise of the radioactivity in 
the water, air and ground, registered a sudden rise in morbidity in EU and USA. We would like 
to mention the genetic factor in etiology of PTC. It has been recently shown that these tumors 
commonly have one of three genetic alterations: BRAF point mutations, RET/PTC 
rearrangements, or RAS point mutations. This factor has to have a substantial role in precocious 
diagnosis of the cancer and prognosis after the chirurgical treatment.  
Aim of the study. To elucidate the role of the genetic modifications in pathogenesis and 
cancerogenesis of the disease 
Materials and methods. We performed a retrospective study on a group of 50 patients with 
thyroid cancer, who were investigated: clinical, ultrasound, histological and laboratory (thyroid 
hormone level) and treated in the oncological “Head and neck” department of the Institute of 
Oncology between December 15- May 30, 2019 . The study included primarily diagnosed cases 
with CPT after surgical intervention. Data on the main risk factors, demography and tumor 
location have been collected from medical records. We will classify the patients after age, sex, 
cancer stage, evolution rate, data about the family anamnesis: the presence if the thyroid 
nodular disease and the presence of another neoplastic processes in relatives.  
Results. 83% of patients were diagnosed with CPT, 80% are female, middle age of 
involvement of 51-60 years old (38%). We observe hypoplasia of the thyroid gland on 6 
patients (12%); hyperplasia of grade l-ll on 27 patients (54%); hyperplasia of grade lll-lV on 
16 patients (33%). According to hormonal levels, euthyroidism, had 18 patients (37%); 
hypothyroidism 10 patients (21%); hypothyroidism 21 patients (42%). CPT patients were 
diagnosed in pTNM following stages: st.l T1N0M0, 7 patients (15%); st.ll T2N0M0, 22 
patients (45%); st.lll T3N1M0, 15 patients (30%); st.lV T4N1M1, 5 patients (10%). From the 
studied group, 19 patients have relatives with nodular pathology of the thyroid gland (37%). 
